Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
about
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer
P2860
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Overall survival with crizotin ...... de cohort retrospective study.
@ast
Overall survival with crizotin ...... de cohort retrospective study.
@en
type
label
Overall survival with crizotin ...... de cohort retrospective study.
@ast
Overall survival with crizotin ...... de cohort retrospective study.
@en
prefLabel
Overall survival with crizotin ...... de cohort retrospective study.
@ast
Overall survival with crizotin ...... de cohort retrospective study.
@en
P2093
P2860
P50
P356
P1433
P1476
Overall survival with crizotin ...... de cohort retrospective study.
@en
P2093
Alexandra Langlais
Anne Madroszyk-Flandin
Benjamin Besse
Bertrand Mennecier
Denis Moro-Sibilot
Eric Dansin
Franck Morin
François Guichard
Jacques Cadranel
Josiane Otto
P2860
P304
21903-21917
P356
10.18632/ONCOTARGET.15746
P407
P577
2017-03-01T00:00:00Z